Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Private Label Mucinex March Reaches Two Formulations

This article was originally published in The Tan Sheet

Executive Summary

Perrigo starts first shipments of a 1,200mg guaifenesin/60mg DXM generic of Mucinex DM, indicated to control coughs and to break up mucus.

You may also be interested in...



Reckitt Ups 2018 Guidance On Mucinex 'All-In-One,' China Platform Gains

Max Cold & Flu All-In-One is the first Mucinex product providing an “all-in-one-and-done proposition" and is expected to offset the impact of private label products. Mucinex plus growth and expansion plans for infant formula spark increase in firm’s 2018 forecast.

Reckitt Ups 2018 Guidance On Mucinex 'All-In-One,' China Platform Gains

Max Cold & Flu All-In-One is the first Mucinex product providing an “all-in-one-and-done proposition" and is expected to offset the impact of private label products. Mucinex plus growth and expansion plans for infant formula spark increase in firm’s 2018 forecast.

Reckitt Boosts 2018 Guidance A Year After Gaining China Platform With MJN

Reckitt reports infant formula sales in China drove a 9% pro-forma increase in its child nutrition segment in second quarter, prompting a revenue forecast on the higher end of a 2%-3% projection. Firm says new infant formula and VMS products, including an improved Move Free formula, will continue to strengthen the sector.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108317

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel